Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 56.83B 52.84B 48.1B 90.74B 6,161B 91.18B 636B 249B 3,136B 239B 234B 10,074B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.28B 67.2B 61.17B 115B 7,836B 116B 809B 316B 3,988B 304B 297B 12,812B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
Sep. 01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07
Andres Rodrigo BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.83%	+2.56%	+39.44%	+108.64%	1,043B
JOHNSON & JOHNSON	+1.93%	+1.07%	+37.82%	+65.85%	618B
ABBVIE INC.	+1.49%	+6.36%	+19.56%	+86.50%	481B
MERCK & CO., INC.	+2.26%	+1.24%	+68.52%	+40.16%	351B
ROCHE HOLDING AG	+1.45%	+2.52%	+22.83%	+44.22%	338B
NOVARTIS AG	+1.17%	+0.88%	+11.83%	+34.76%	269B
ASTRAZENECA PLC	+0.89%	-0.28%	-6.31%	+9.65%	244B
AMGEN INC.	+1.82%	+1.87%	+40.82%	+55.11%	220B
GILEAD SCIENCES, INC.	+2.77%	+2.49%	+27.84%	+102.26%	182B
Average	+0.63%	+0.28%	+29.15%	+60.79%	416.3B
Weighted average by Cap.	+0.36%	+0.60%	+32.41%	+71.30%

	2018	2019
Net sales	15.79B 14.09B 13.1B 11.93B 22.5B 1,528B 22.61B 158B 61.71B 778B 59.28B 57.98B 2,498B	16.09B 14.36B 13.35B 12.16B 22.93B 1,557B 23.04B 161B 62.89B 793B 60.41B 59.09B 2,546B
Net income	-5.1B -4.55B -4.23B -3.85B -7.26B -493B -7.3B -50.93B -19.92B -251B -19.14B -18.72B -806B	-5.27B -4.71B -4.37B -3.98B -7.51B -510B -7.55B -52.68B -20.6B -260B -19.79B -19.36B -834B
Net Debt	21.89B 19.54B 18.17B 16.54B 31.2B 2,119B 31.35B 219B 85.56B 1,078B 82.2B 80.4B 3,464B	17.3B 15.45B 14.36B 13.07B 24.67B 1,675B 24.78B 173B 67.64B 852B 64.98B 63.56B 2,738B

End-of-day quote NYSE
- ^USD	-